Cargando…

IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial

AIMS: Given recent suggestions that serum levels of insulin‐like growth factor‐binding protein 7 (IGFBP7) may identify patients who derive greater cardiorenal benefits from treatment with sodium‐glucose transport 2 inhibitors (SGLT2i), this exploratory sub‐analysis of the EMPA‐HEART CardioLink‐6 ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Puar, Pankaj, Mistry, Nikhil, Connelly, Kim A., Yan, Andrew T., Quan, Adrian, Teoh, Hwee, Pan, Yi, Verma, Raj, Hess, David A., Verma, Subodh, Mazer, C. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192263/
https://www.ncbi.nlm.nih.gov/pubmed/37038626
http://dx.doi.org/10.1002/ehf2.14335
_version_ 1785043591009140736
author Puar, Pankaj
Mistry, Nikhil
Connelly, Kim A.
Yan, Andrew T.
Quan, Adrian
Teoh, Hwee
Pan, Yi
Verma, Raj
Hess, David A.
Verma, Subodh
Mazer, C. David
author_facet Puar, Pankaj
Mistry, Nikhil
Connelly, Kim A.
Yan, Andrew T.
Quan, Adrian
Teoh, Hwee
Pan, Yi
Verma, Raj
Hess, David A.
Verma, Subodh
Mazer, C. David
author_sort Puar, Pankaj
collection PubMed
description AIMS: Given recent suggestions that serum levels of insulin‐like growth factor‐binding protein 7 (IGFBP7) may identify patients who derive greater cardiorenal benefits from treatment with sodium‐glucose transport 2 inhibitors (SGLT2i), this exploratory sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized controlled trial evaluated the association between serum levels of IGFBP7 and empagliflozin‐mediated left ventricular mass regression. METHODS AND RESULTS: The EMPA‐HEART CardioLink‐6 trial used gold‐standard cardiac magnetic resonance imaging to detect change in left ventricular mass indexed to body surface area (LVMi) following 6 months of treatment with empagliflozin or matching placebo in 97 patients with type 2 diabetes and coronary artery disease. Serum samples were collected at baseline and analysed for IGFBP7 using an enzyme‐linked immunosorbent assay. A multivariate linear regression model was used to assess the association between IGFBP7 and baseline LVMi. A linear model adjusting for baseline differences in LVMi was used to test the relationship between baseline IGFBP7 level, change in LVMi over 6 months, and treatment arm. Of the 97 patients enrolled, 74 had complete covariate data and were included in our analysis. No association between baseline IGFBP7 and baseline LVMi was found [baseline LVMi: 0.14 g/m(2) (95% CI: −0.29 g/m(2) to 0.57 g/m(2)) per 1 ng/mL higher baseline IGFBP7]. In addition, no difference between patients treated with empagliflozin versus matching placebo was found when evaluating the association between serum IGFBP7, 6 month change in LVMi, and treatment arm [empagliflozin 6 month change in LVMi: 0.25 g/m(2) (95% CI: −0.17 g/m(2) to 0.67 g/m(2)) per 1 ng/mL higher IGFBP7 vs. matching placebo 6 month change in LVMi: 0.07 g/m(2) (95% CI: −0.21 g/m(2) to 0.35 g/m(2)) per 1 ng/mL higher IGFBP7; P (interaction) = 0.49]. Additional sensitivity analysis assessing IGFBP7 as a categorical variable (above/below the median) showed no significant association between IGFBP7, 6 month change in LVMi, and treatment arm. CONCLUSIONS: Our study provides insight into the generalizability of IGFBP7 as a surrogate marker of cardiac remodelling in patients with type 2 diabetes and coronary artery disease. Our results suggest that SGLT2i‐mediated reverse cardiac remodelling may be independent of IGFBP7 levels. Further investigations evaluating the association between IGFBP7 and SGLT2i are suggested to understand if and how IGFBP7 levels may modulate benefits received from SLGT2i.
format Online
Article
Text
id pubmed-10192263
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101922632023-05-19 IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial Puar, Pankaj Mistry, Nikhil Connelly, Kim A. Yan, Andrew T. Quan, Adrian Teoh, Hwee Pan, Yi Verma, Raj Hess, David A. Verma, Subodh Mazer, C. David ESC Heart Fail Short Communications AIMS: Given recent suggestions that serum levels of insulin‐like growth factor‐binding protein 7 (IGFBP7) may identify patients who derive greater cardiorenal benefits from treatment with sodium‐glucose transport 2 inhibitors (SGLT2i), this exploratory sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized controlled trial evaluated the association between serum levels of IGFBP7 and empagliflozin‐mediated left ventricular mass regression. METHODS AND RESULTS: The EMPA‐HEART CardioLink‐6 trial used gold‐standard cardiac magnetic resonance imaging to detect change in left ventricular mass indexed to body surface area (LVMi) following 6 months of treatment with empagliflozin or matching placebo in 97 patients with type 2 diabetes and coronary artery disease. Serum samples were collected at baseline and analysed for IGFBP7 using an enzyme‐linked immunosorbent assay. A multivariate linear regression model was used to assess the association between IGFBP7 and baseline LVMi. A linear model adjusting for baseline differences in LVMi was used to test the relationship between baseline IGFBP7 level, change in LVMi over 6 months, and treatment arm. Of the 97 patients enrolled, 74 had complete covariate data and were included in our analysis. No association between baseline IGFBP7 and baseline LVMi was found [baseline LVMi: 0.14 g/m(2) (95% CI: −0.29 g/m(2) to 0.57 g/m(2)) per 1 ng/mL higher baseline IGFBP7]. In addition, no difference between patients treated with empagliflozin versus matching placebo was found when evaluating the association between serum IGFBP7, 6 month change in LVMi, and treatment arm [empagliflozin 6 month change in LVMi: 0.25 g/m(2) (95% CI: −0.17 g/m(2) to 0.67 g/m(2)) per 1 ng/mL higher IGFBP7 vs. matching placebo 6 month change in LVMi: 0.07 g/m(2) (95% CI: −0.21 g/m(2) to 0.35 g/m(2)) per 1 ng/mL higher IGFBP7; P (interaction) = 0.49]. Additional sensitivity analysis assessing IGFBP7 as a categorical variable (above/below the median) showed no significant association between IGFBP7, 6 month change in LVMi, and treatment arm. CONCLUSIONS: Our study provides insight into the generalizability of IGFBP7 as a surrogate marker of cardiac remodelling in patients with type 2 diabetes and coronary artery disease. Our results suggest that SGLT2i‐mediated reverse cardiac remodelling may be independent of IGFBP7 levels. Further investigations evaluating the association between IGFBP7 and SGLT2i are suggested to understand if and how IGFBP7 levels may modulate benefits received from SLGT2i. John Wiley and Sons Inc. 2023-04-10 /pmc/articles/PMC10192263/ /pubmed/37038626 http://dx.doi.org/10.1002/ehf2.14335 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Short Communications
Puar, Pankaj
Mistry, Nikhil
Connelly, Kim A.
Yan, Andrew T.
Quan, Adrian
Teoh, Hwee
Pan, Yi
Verma, Raj
Hess, David A.
Verma, Subodh
Mazer, C. David
IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
title IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
title_full IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
title_fullStr IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
title_full_unstemmed IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
title_short IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
title_sort igfbp7 and left ventricular mass regression: a sub‐analysis of the empa‐heart cardiolink‐6 randomized clinical trial
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192263/
https://www.ncbi.nlm.nih.gov/pubmed/37038626
http://dx.doi.org/10.1002/ehf2.14335
work_keys_str_mv AT puarpankaj igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial
AT mistrynikhil igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial
AT connellykima igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial
AT yanandrewt igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial
AT quanadrian igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial
AT teohhwee igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial
AT panyi igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial
AT vermaraj igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial
AT hessdavida igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial
AT vermasubodh igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial
AT mazercdavid igfbp7andleftventricularmassregressionasubanalysisoftheempaheartcardiolink6randomizedclinicaltrial